Philippines CMDL: Device Listing for Non-Sale Purposes

1. Key takeaways

The CMDL, or Certificate of Medical Device Listing, is issued for medical devices that enter the Philippines for research, clinical trials, exhibition, donation or comparable purposes and are not intended for sale. It replaces the CMDN or CMDR only on the condition that the device is not placed on the market for sale. Once the device is redirected to commercial sale, the CMDN or CMDR route applies again, and the CMDL provides no continuing basis for distribution.

The misunderstanding that causes the most difficulty is treating the CMDL as a product exemption. It is not. It is a purpose exemption attached to a specific import or use, and its scope ends when the purpose ends. Devices that arrive under a CMDL and then remain in the country for commercial use create a compliance gap that post-market surveillance can trace, because the registration record and the distribution record do not match.

• Purpose-based authorisation: research, clinical trials, exhibition, donation, not for sale.
• Issued under AO No. 2018-0002, Section IV, item 6.
• Clinical research on Class B, C and D devices also needs a CIA, and IVDs need a CPSA.
• Ethics review is tiered by site count: one to two sites use a Level III PHREB accredited REC, three or more sites go to SJREB.
• Safety reporting runs to 7 calendar days for a serious adverse event and 15 calendar days for a device deficiency.

2. Legal basis

The definition sits in the same section of AO No. 2018-0002 that defines the CMDN and CMDR, which is useful because it shows the three authorisations were drafted as one family with different purposes rather than as separate regimes. Clinical research adds a second layer of approvals that runs in parallel with the listing and is not satisfied by it.

3. Expert insights

Insight one: the CMDL exempts a purpose, not a product.

The distinction is simple to state and easy to lose in practice. The same device that enters under a CMDL for a clinical trial needs a CMDN or CMDR the moment it is sold commercially after the trial closes. A recurring compliance break in projects is a trial that finishes, a device that is then sold from remaining stock, and no registration certificate anywhere in the file. Under FDA post-market surveillance this is a traceable violation, because the import record references a listing certificate that never authorised distribution.

Insight two: clinical trial approvals and product registration are parallel tracks.

Running a device study in the Philippines requires more than a CMDL. The device class determines a separate approval: Class B, C and D devices need a Clinical Investigation Approval (CIA), and Class B, C and D IVDs need a Clinical Performance Study Approval (CPSA). Ethics review is tiered by the number of sites, with one or two sites going to a Level III PHREB accredited REC and three or more sites going to SJREB. These approvals operate alongside the product registration track rather than in sequence with it, and treating the two as one chain is a common cause of schedule slippage.

Insight three: exhibition and donation carry compliance detail that is routinely underestimated.

Attending a trade fair or donating equipment to a hospital looks like activity outside the commercial market, but in the Philippines these fall within conduct controlled by Section 11 of RA 9711, which covers transfer and non-consumer use among the prohibited acts. The CMDL is the instrument that gives such activity a lawful basis. Our recommendation is straightforward: whenever a device enters the country in physical form, confirm whether a CMDL is required before shipping, regardless of whether any money changes hands. Consignment stock, evaluation units and demonstration sets all raise the same question.

Insight four: post-market obligations for research devices are not fully set aside.

Even in a research setting, the draft implementing rules for clinical investigations and IVD clinical performance studies set explicit safety reporting requirements. A serious adverse event must be reported no later than 7 calendar days after the sponsor first becomes aware of it, and a device deficiency must be reported no later than 15 calendar days. This differs from the vigilance timelines that apply to commercially distributed products, so a separate procedure is needed rather than an adaptation of the commercial one.

4. Practical recommendations

• Put the sale question into the import decision table. Before each consignment, record the intended purpose, whether research, trial, exhibition, donation or sale, and map that purpose to the authorisation type. The table should be signed off by the same function that controls shipping, not only by regulatory affairs.
• Schedule clinical trials and product registration separately. The CMDL with a CIA for a study and the CMDR for commercial supply are two document sets and two internal workflows. Combining them into one schedule tends to produce a plan that is wrong for both.
• Start commercial registration six months before the trial closes. Waiting for trial data before beginning CSDT preparation typically pushes overall market entry back by a year, and the delay is avoidable in most device programmes where the technical content is already substantially complete.

5. Verification checklist

• □ Confirm that the purpose of entry is genuinely non-sale, as an internal determination recorded before shipment.
• □ Confirm whether a CMDL is required under Section IV, item 6 of AO No. 2018-0002.
• □ Confirm whether clinical research is involved; if so, confirm the CIA requirement for Class B, C and D devices or the CPSA requirement for IVDs.
• □ Confirm the ethics review tier by site count: one to two sites use a PHREB Level III REC, three or more use SJREB.
• □ Confirm the safety reporting timelines: serious adverse events within 7 calendar days, device deficiencies within 15 calendar days.
• □ Confirm the registration route to be used before any conversion to sale, whether CMDN or CMDR by class.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com